View Older Stories View More Recent Stories

Nov 21, 2022 04:05PM Adagene Appoints Cuong Do to Board of Directors and Audit Committee
Nov 21, 2022 04:05PM Adagene Appoints Cuong Do to Board of Directors and Audit Committee
Nov 10, 2022 09:06AM Adagene Inc. (ADAG) Reports Data on ADG116
Nov 10, 2022 09:04AM Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors
Nov 10, 2022 09:04AM Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors
Oct 11, 2022 04:03PM Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November
Oct 11, 2022 04:03PM Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November
Sep 12, 2022 05:23AM Adagene Inc. (ADAG) Reports Strong Interim Monotherapy Data of ADG126
Sep 10, 2022 04:13AM Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors
Sep 10, 2022 04:13AM Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors
Aug 30, 2022 05:25PM Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates
Aug 30, 2022 05:25PM Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates
Jun 29, 2022 04:05PM Adagene Inc. (ADAG) Announces $10M Share Buyback
Jun 29, 2022 04:05PM Adagene Announces Authorization of Share Repurchase Program up to US$10 Million
Jun 29, 2022 04:05PM Adagene Announces Authorization of Share Repurchase Program up to US$10 Million
May 26, 2022 05:04PM Adagene Inc. (ADAG) Reports Publication of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of ADG126,
May 26, 2022 05:00PM Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels
May 26, 2022 05:00PM Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels
May 12, 2022 07:00AM Adagene to Participate in Investor Conferences in May and June
May 12, 2022 07:00AM Adagene to Participate in Investor Conferences in May and June
Apr 8, 2022 01:11PM Adagene Inc. (ADAG) Presents Preclical Data Demonstrating First and Best-in-Class Potential for Antibody Candidates at AACR
Apr 8, 2022 01:09PM Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022
Apr 8, 2022 01:09PM Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022
Mar 31, 2022 08:30AM Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update
Mar 31, 2022 08:30AM Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update
Mar 16, 2022 07:00AM Adagene Inc. (ADAG) Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
Mar 16, 2022 07:00AM Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
Mar 8, 2022 05:28PM Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting
Mar 2, 2022 06:01AM Adagene Inc. (ADAG) Enters SAFEbody Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates
Mar 2, 2022 06:00AM Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates
Feb 8, 2022 07:00AM Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
Feb 2, 2022 04:23PM Adagene Inc. (ADAG) Announces Board and Management Appointments
Feb 2, 2022 04:05PM Adagene Announces Board and Management Appointments to Support Pipeline Growth
Jan 27, 2022 07:00AM Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116
May 6, 2021 04:05PM Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update
Feb 10, 2021 04:05PM Exelixis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
View More Recent Stories View Older Stories